Due to the lack of biomarkers predictive of response to atezolizumab-bevacizumab, the standard of care for advanced HCC, we analyzed baseline and early on-treatment variation of peripheral lymphocyte populations of 37 prospective patients treated by atezolizumab-bevacizumab and in 15 prospective patients treated by sorafenib or lenvatinib (TKIs). RNAseq analysis followed by RT-PCR validation on patients-derived PBMC was also performed. At first imaging, re-evaluation 13 patients receiving atezolizumab-bevacizumab, showed an objective response, 17 stable disease, while 7 were nonresponders. Baseline CD8+ and CD8+PD-L1+ peripheral lymphocytes were lower in responders versus nonresponders (T-test, p = 0.012 and 0.004, respectively). At 3 weeks, 28 of 30 responders displayed a rise of CD8+PD1+ lymphocytes with a positive mean fold change of 4.35 (+/- 5.6 SD), whereas 6 of 7 nonresponders displayed a negative fold change of 0.89 (+/- 0.84 SD). These changes were not observed in patients treated by TKIs. TRIM56, TRIM16, TRIM64, and Ki67 mRNAs were validated as upregulated in responders versus nonresponders after 3 weeks after treatment start, providing possible evidence of immune activation. Baseline CD8+ and CD8+PD-L1+ peripheral lymphocytes and early changes in CD8+PD1+ lymphocytes predict response to atezolizumab-bevacizumab providing noninvasive markers to complement clinical practice in the very early phases of treatment of HCC patients.PBMCs represent important elements in assessing the response to immune checkpoint inhibitors. Their analyses through flow cytometry show that baseline CD8+, CD8+PD-L1+, and an early increase in CD8+PD1+ peripheral lymphocytes after the first drug infusion, reliably predict the response to atezolizumab-bevacizumab evaluated by imaging in advanced hepatocellular carcinoma. image

Circulating CD8 lymphocytes predict response to atezolizumab–bevacizumab in hepatocellular carcinoma / Gramantieri L.; Suzzi F.; Bassi C.; D'Abundo L.; Tovoli F.; Bruccoleri M.; Marseglia M.; Alimenti E.; Fornari F.; Negrini M.; Iavarone M.; Piscaglia F.; Giovannini C.. - In: EUROPEAN JOURNAL OF IMMUNOLOGY. - ISSN 1521-4141. - ELETTRONICO. - 54:2(2024), pp. 1-10. [10.1002/eji.202350637]

Circulating CD8 lymphocytes predict response to atezolizumab–bevacizumab in hepatocellular carcinoma

Gramantieri L.
;
Suzzi F.;Tovoli F.;Fornari F.;Piscaglia F.;Giovannini C.
2024

Abstract

Due to the lack of biomarkers predictive of response to atezolizumab-bevacizumab, the standard of care for advanced HCC, we analyzed baseline and early on-treatment variation of peripheral lymphocyte populations of 37 prospective patients treated by atezolizumab-bevacizumab and in 15 prospective patients treated by sorafenib or lenvatinib (TKIs). RNAseq analysis followed by RT-PCR validation on patients-derived PBMC was also performed. At first imaging, re-evaluation 13 patients receiving atezolizumab-bevacizumab, showed an objective response, 17 stable disease, while 7 were nonresponders. Baseline CD8+ and CD8+PD-L1+ peripheral lymphocytes were lower in responders versus nonresponders (T-test, p = 0.012 and 0.004, respectively). At 3 weeks, 28 of 30 responders displayed a rise of CD8+PD1+ lymphocytes with a positive mean fold change of 4.35 (+/- 5.6 SD), whereas 6 of 7 nonresponders displayed a negative fold change of 0.89 (+/- 0.84 SD). These changes were not observed in patients treated by TKIs. TRIM56, TRIM16, TRIM64, and Ki67 mRNAs were validated as upregulated in responders versus nonresponders after 3 weeks after treatment start, providing possible evidence of immune activation. Baseline CD8+ and CD8+PD-L1+ peripheral lymphocytes and early changes in CD8+PD1+ lymphocytes predict response to atezolizumab-bevacizumab providing noninvasive markers to complement clinical practice in the very early phases of treatment of HCC patients.PBMCs represent important elements in assessing the response to immune checkpoint inhibitors. Their analyses through flow cytometry show that baseline CD8+, CD8+PD-L1+, and an early increase in CD8+PD1+ peripheral lymphocytes after the first drug infusion, reliably predict the response to atezolizumab-bevacizumab evaluated by imaging in advanced hepatocellular carcinoma. image
2024
Circulating CD8 lymphocytes predict response to atezolizumab–bevacizumab in hepatocellular carcinoma / Gramantieri L.; Suzzi F.; Bassi C.; D'Abundo L.; Tovoli F.; Bruccoleri M.; Marseglia M.; Alimenti E.; Fornari F.; Negrini M.; Iavarone M.; Piscaglia F.; Giovannini C.. - In: EUROPEAN JOURNAL OF IMMUNOLOGY. - ISSN 1521-4141. - ELETTRONICO. - 54:2(2024), pp. 1-10. [10.1002/eji.202350637]
Gramantieri L.; Suzzi F.; Bassi C.; D'Abundo L.; Tovoli F.; Bruccoleri M.; Marseglia M.; Alimenti E.; Fornari F.; Negrini M.; Iavarone M.; Piscaglia F.; Giovannini C.
File in questo prodotto:
File Dimensione Formato  
Eur J Immunol - 2023 - Gramantieri - Circulating CD8 lymphocytes predict respo.pdf

accesso aperto

Tipo: Versione (PDF) editoriale
Licenza: Licenza per Accesso Aperto. Creative Commons Attribuzione - Non commerciale - Non opere derivate (CCBYNCND)
Dimensione 2.21 MB
Formato Adobe PDF
2.21 MB Adobe PDF Visualizza/Apri
eji5648-sup-0001-suppmat.pdf

accesso aperto

Tipo: File Supplementare
Licenza: Licenza per Accesso Aperto. Creative Commons Attribuzione - Non commerciale - Non opere derivate (CCBYNCND)
Dimensione 394.55 kB
Formato Adobe PDF
394.55 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/954144
Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 1
  • ???jsp.display-item.citation.isi??? 1
social impact